Is Pharma Research Worse Than Chance?

A speculative, generative essay: the two most exciting 21st-century psych developments (ketamine, MDMA) were found by recreational users, not intentional research — why is the abusers' selection process better? Hypothesis: the brain has few high-level variables, so any drug that 'smacks the brain really hard' in some direction will treat some disorder (cf. ECT); carefully-researched drugs are optimized for tiny side effects and thus tiny treatment effects (the magic-bullet dream is false). Suggests pharma should hunt for the wackiest-effect chemicals and then check for disease treatment, with an honest counterargument (ketamine's non-psychoactive metabolite).

Quality 72 · Strong. High-Strong: an original, memorable, portable reframe (side-effect-size ≈ treatment-effect-size; 'smack the brain hard') that prefigured the psychedelic-research wave; speculative and bounded (he offers counterarguments, doesn't resolve), so below the Excellent floor. 72.

Claude’s paradigm shift 54 · Moderate. A fresh, non-obvious hypothesis about drug-discovery epistemics. B54.

Real-world impact 2 · Minor. The 'pharma worse than chance' framing is cited within the psychopharm/psychedelics discourse; no material reach. RWI2.